Brian Park, PharmD

The investigational oral microbiome therapeutic SER-109 was found to be safe and effective for the prevention of recurrent CDI.

The vaccine candidate contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with an adjuvant.